FDA Warns Of Risks To Babies From HIV Drug Kaletra

Law360, New York (March 8, 2011, 5:12 PM EST) -- The U.S. Food and Drug Administration issued new warnings last month for Abbott Laboratories' Kaletra after serious health problems were reported in premature babies receiving the oral anti-HIV drug.

A new warning on the Kaletra label approved by the FDA on Feb. 24 says premature babies should not be given Kaletra until 14 days after their original due date — not their actual date of birth — and that infants younger than 14 days of age should only receive the drug if a doctor believes the...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.